Cellectis
- Company typePublic
- Founded1999
- HeadquartersParis, France
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
Cellectis firmographics
Firmographics- Name
- Cellectis
- Legal name
- Cellectis S.A.
- Website
- https://cellectis.com
- Company type
- Public
- Founded year
- 1999
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
Cellectis industry classification
Industry- Product category
- Cell Therapy Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB)
- akta.pro secondary industries
- Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), CAR-T & TCR-T Therapies (HLAAABAC), Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC)
Keywords
Where Cellectis is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices3 records
Markets served
Cellectis business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Revenue model
- Collaboration and Licensing Revenue: Revenue generated from strategic partnerships including the AstraZeneca Joint Research and Collaboration Agreement and licensing agreements with Servier/Allogene for CD19 CAR-T products. Cellectis receives development and sales milestone payments as well as royalties on net sales of licensed products.
- Global Offering and Equity Financing: Capital raised through global offerings of ADSs on Nasdaq and ordinary shares on Euronext Paris, including exercise of underwriters' option to purchase additional shares.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | One time/ perpetual license | Potential commercial product pricing for lasme-cel in r/r B-ALL |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Cellectis product offering
Product offeringCore offering
Cellectis is a clinical-stage biotechnology company that develops allogeneic (off-the-shelf) CAR-T cell therapy product candidates for cancer using its proprietary TALEN® gene editing platform. Its lead candidates are lasme-cel (UCART22), a CD22-targeting therapy for relapsed/refractory B-cell acute lymphoblastic leukemia, and eti-cel (UCART20x22), a dual CD20/CD22-targeting therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. The company also licenses its gene editing and manufacturing capabilities to strategic pharmaceutical partners such as AstraZeneca, Servier, and Allogene.
Product overview
Cellectis is a clinical-stage biotechnology company that has developed a portfolio of allogeneic CAR-T cell therapy product candidates enabled by its proprietary gene editing platform. The core products include lasme-cel (UCART22), a CD22-targeting allogeneic CAR-T for relapsed/refractory B-cell acute lymphoblastic leukemia currently in pivotal Phase 2 trials, and eti-cel (UCART20x22), a dual CD20/CD22 targeting allogeneic CAR-T for relapsed/refractory non-Hodgkin lymphoma in Phase 1. The technology portfolio encompasses TALEN® gene editing, TALE-based epigenetic editing (TALEM), TALE base editors (TALEB), and CssDNA non-viral gene editing processes, all powered by proprietary PulseAgile electroporation technology. The company operates end-to-end in-house GMP manufacturing facilities across three locations. Cema-cel (derived from UCART19 licensed to Servier/Allogene) represents a partnered anti-CD19 CAR-T product.
Differentiator
Problem solved
Functional benefit
Brands
- TALEN: Cellectis's flagship gene editing technology for creating CAR T therapies
- UCART
- lasme-cel
- eti-cel
- PulseAgile
Products and services
- Lasme-cel (UCART22) CD22-targeting allogeneic CAR-T cell therapy product candidate for treating relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) in transplant-ineligible patients in the third line or beyond (3L+). Uses TALEN gene editing to create off-the-shelf universal CAR-T cells from healthy donor T-cells. FDA RMAT designated.
- Eti-cel (UCART20x22) Dual-targeting allogeneic CAR-T cell therapy product candidate simultaneously targeting CD20 and CD22 antigens for relapsed/refractory B-cell non-Hodgkin lymphoma (r/r NHL) in patients who have failed at least two prior lines of therapy including CD19 CAR-T. The first allogeneic dual CAR-T targeting both CD20 and CD22 antigens.
- TALEN Gene Editing Technology Proprietary Transcription Activator-Like Effector Nuclease (TALEN) gene editing technology enabling precise DNA modifications in T-cells. Used to engineer allogeneic CAR-T therapies and licensed to pharmaceutical partners including AstraZeneca, Servier, and Allogene for co-development of cell and gene therapy products.
- PulseAgile Electroporation Technology Proprietary electroporation technology using precise electrical pulses to create temporary pores in CAR T-cells, allowing TALEN enzymes to enter and make precise gene edits without harming T-cells during processing.
Quantifiable outcome
- 100% overall response rate (ORR) in lasme-cel target Phase 2 population (n=7)
- +7 more outcomes
Companies that use Cellectis
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
Cellectis technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Cellectis partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered flagship, core and minor.
- AstraZenecaflagshipJoint Research and Collaboration Agreement leveraging Cellectis' gene editing expertise and manufacturing capabilities to develop up to 10 novel cell and gene therapy products for areas of high unmet medical need, including oncology, immunology and rare genetic disorders. Activities are progressing under this collaboration with three programs initiated.
- ServiercoreLicense, Development and Commercialization Agreement (signed March 6, 2019) for anti-CD19 allogeneic CAR-T products. Servier sublicensed rights to Allogene for certain territories. Cellectis eligible for up to $340 million in development and sales milestones plus low double-digit royalties on net sales of licensed CD19 products including cema-cel. In December 2025, arbitration ruled on partial termination for UCART19 V1 (ALLO-501).
- Allogene TherapeuticscoreSublicensee of Servier for anti-CD19 CAR-T products (cema-cel) derived from Cellectis' UCART19 platform. Allogene is conducting the pivotal ALPHA3 trial for cema-cel in first-line consolidation for LBCL. In December 2025, Allogene won arbitration securing full development and commercial control of cema-cel in US, EU, and UK.
- Primera (inferred from partnership mention)minorListed as global strategic partner in Cellectis' intellectual property section.
Scale indicators11 records
Recent moves6 records
Expansion highlights6 records
Cellectis competitors and assessment
Company assessmentDirect peers
- Allogene Therapeutics: Allogene is the closest direct peer, developing allogeneic CAR-T therapies including cema-cel derived from Cellectis' UCART19 platform licensed via Servier. It competes head-to-head in the allogeneic CAR-T space with overlapping CD19 and CD20/CD22 programs and shared scientific lineage.
- CRISPR Therapeutics: CRISPR Therapeutics develops gene-edited allogeneic CAR-T therapies (e.g., CTX112, CTX131) using CRISPR/Cas9, directly competing with Cellectis in the allogeneic CAR-T space and sharing the same target indications in B-cell malignancies.
- Fate Therapeutics: Fate Therapeutics develops off-the-shelf iPSC-derived cell therapies including CAR-T candidates, directly competing in the allogeneic/multiplexed-engineered cell therapy category with similar B-cell malignancy targets and platform-based differentiation.
- Caribou Biosciences: Caribou Biosciences develops allogeneic CAR-T cell therapies (e.g., CB-010, CB-012) using CRISPR-based gene editing, directly competing in the allogeneic CAR-T space with similar oncology indications and platform-driven differentiation.
- Precision BioSciences: Precision BioSciences develops allogeneic CAR-T therapies using its ARCUS gene editing platform, a direct competitor to Cellectis' TALEN platform in the off-the-shelf CAR-T category with comparable B-cell malignancy programs.
Broad incumbents
- Adaptimmune Therapeutics: Adaptimmune develops engineered T-cell receptor (TCR) therapies for solid tumors, a broader cell therapy peer with overlapping platform engineering expertise and clinical-stage oncology pipeline though focused on TCR rather than CAR-T.
- Iovance Biotherapeutics: Iovance is a commercial-stage cell therapy company focused on tumor-infiltrating lymphocyte (TIL) therapies, a Cellectis collaboration partner (IOV-4001 PD-1 inactivated TIL) operating in the broader engineered cell therapy space.
- Bristol Myers Squibb: BMS markets Breyanzi and Abecma, leading autologous CAR-T therapies in B-cell malignancies, representing the incumbent standard of care that Cellectis' allogeneic products must displace or complement.
- Gilead Sciences (Kite): Gilead's Kite Pharma subsidiary markets Yescarta and Tecartus, the dominant autologous CAR-T franchises in lymphoma and ALL, representing the primary competitive incumbent Cellectis aims to disrupt with off-the-shelf alternatives.
Emerging players
- Beam Therapeutics: Beam Therapeutics develops base editing therapies with overlap to Cellectis' TALEB base editor platform, representing a peer in next-generation gene editing though focused on in vivo applications rather than ex vivo CAR-T.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Cellectis social profiles
Digital presenceCellectis financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cellectis leadership team
Management profileNumber of profiles
Profiles11 records
Cellectis funding detail
Funding detailFunding overview
Funding rounds9 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cellectis M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cellectis
What does Cellectis do?
Cellectis is a clinical-stage biotechnology company that develops allogeneic (off-the-shelf) CAR-T cell therapy product candidates for cancer using its proprietary TALEN® gene editing platform. Its lead candidates are lasme-cel (UCART22), a CD22-targeting therapy for relapsed/refractory B-cell acute lymphoblastic leukemia, and eti-cel (UCART20x22), a dual CD20/CD22-targeting therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. The company also licenses its gene editing and manufacturing capabilities to strategic pharmaceutical partners such as AstraZeneca, Servier, and Allogene.
Is Cellectis a public or private company?
Cellectis is a public company. It is classified as public and is currently operating.
When was Cellectis founded?
Cellectis was founded in 1999. It employs 101 to 250 people.
Where is Cellectis based?
Cellectis is headquartered in Paris, France, in the Europe region.
How does Cellectis make money?
Two revenue lines are on record. Collaboration and Licensing Revenue is the primary driver. The others are global Offering and Equity Financing.
Who are Cellectis's main competitors?
Direct peers on record are Allogene Therapeutics, CRISPR Therapeutics, Fate Therapeutics, Caribou Biosciences and Precision BioSciences. Broad incumbents are Adaptimmune Therapeutics, Iovance Biotherapeutics, Bristol Myers Squibb and Gilead Sciences (Kite). Beam Therapeutics is listed as an emerging player.
Does Cellectis have an API?
No public API is recorded for Cellectis.
What industry is Cellectis in?
Cellectis's product category is Cell Therapy Biopharmaceuticals. Its primary akta.pro industry code is HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf), with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 325414 and its SIC code is 2836.